These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 7447649

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. II. Antiproliferative activity of cyclophosphamide and ifosfamide enantiomers.
    Paprocka M, Radzikowski C.
    Arch Immunol Ther Exp (Warsz); 1986; 34(3):285-91. PubMed ID: 3592932
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Kinetics of both leukemic and normal cell population reduction following 5-azacytidine.
    Presant CA, Vietti T, Valeriote F.
    Cancer Res; 1975 Aug; 35(8):1926-30. PubMed ID: 50128
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of colony-forming cells from bone marrow of leukemic patients by 3-oxauracil.
    Reiner P, Mardiak J, Reinerová M, Ujházy V.
    Neoplasma; 1981 Aug; 28(5):533-9. PubMed ID: 6947140
    [Abstract] [Full Text] [Related]

  • 7. [Colony-forming ability of bone marrow hematopoietic cells in mice with transplanted leukemia during administration of carminomycin].
    Kozinets GI, Ivanova LE, Khanykova OK, Kuznetsova TV, Rudneva NA.
    Eksp Onkol; 1984 Aug; 6(5):59-62. PubMed ID: 6510345
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
    Carlo-Stella C, Mangoni L, Almici C, Caramatti C, Rizzoli V.
    Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
    [Abstract] [Full Text] [Related]

  • 14. 6-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride (C6-galactose mustard), a new alkylating agent with reduced bone marrow toxicity.
    Schein PS, Green D, Dean SW, McPherson E.
    Cancer Res; 1987 Feb 01; 47(3):696-9. PubMed ID: 3802075
    [Abstract] [Full Text] [Related]

  • 15. Plasma interacts with mafosfamide toxicity to normal haematopoietic progenitor cells: impact on in vitro marrow purging.
    Giarratana MC, Gorin NC, Douay L.
    Nouv Rev Fr Hematol (1978); 1995 Feb 01; 37(2):125-30. PubMed ID: 7644349
    [Abstract] [Full Text] [Related]

  • 16. Influence of IL-10 on murine CFU-pre-B formation.
    Fine JS, Macosko HD, Grace MJ, Narula SK.
    Exp Hematol; 1994 Nov 01; 22(12):1188-96. PubMed ID: 7925782
    [Abstract] [Full Text] [Related]

  • 17. The effect of in vivo administration of recombinant methionyl human stem cell factor on the number of human marrow hematopoietic stem cells.
    Tong J, Gordon MS, Srour EF, Cooper RJ, Orazi A, McNiece I, Hoffman R.
    Trans Assoc Am Physicians; 1993 Nov 01; 106():134-44. PubMed ID: 7518622
    [No Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan.
    Patchen ML, Vaudrain T, Correira H, Martin T, Reese D.
    Exp Hematol; 1998 Dec 01; 26(13):1247-54. PubMed ID: 9845381
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.